Last reviewed · How we verify

salicylic acid and ciclopirox olamine

Federal University of São Paulo · FDA-approved active Small molecule

salicylic acid and ciclopirox olamine is a Topical antifungal/keratolytic combination Small molecule drug developed by Federal University of São Paulo. It is currently FDA-approved for Fungal skin infections (dermatophytosis, candidiasis), Onychomycosis (nail fungal infections), Bacterial skin infections. Also known as: anti-seborrheic treatment, anti-dandruff treatment.

Salicylic acid and ciclopirox olamine work synergistically to treat fungal and bacterial skin infections by keratolytic action and antifungal/antibacterial activity.

Salicylic acid and ciclopirox olamine work synergistically to treat fungal and bacterial skin infections by keratolytic action and antifungal/antibacterial activity. Used for Fungal skin infections (dermatophytosis, candidiasis), Onychomycosis (nail fungal infections), Bacterial skin infections.

At a glance

Generic namesalicylic acid and ciclopirox olamine
Also known asanti-seborrheic treatment, anti-dandruff treatment
SponsorFederal University of São Paulo
Drug classTopical antifungal/keratolytic combination
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Salicylic acid is a keratolytic agent that softens and removes dead skin cells, enhancing penetration of the antifungal agent. Ciclopirox olamine is a broad-spectrum antifungal and antibacterial agent that disrupts fungal cell membrane integrity and inhibits fungal enzyme systems. Together, they provide enhanced efficacy against dermatophytes, yeasts, and bacteria in topical skin infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about salicylic acid and ciclopirox olamine

What is salicylic acid and ciclopirox olamine?

salicylic acid and ciclopirox olamine is a Topical antifungal/keratolytic combination drug developed by Federal University of São Paulo, indicated for Fungal skin infections (dermatophytosis, candidiasis), Onychomycosis (nail fungal infections), Bacterial skin infections.

How does salicylic acid and ciclopirox olamine work?

Salicylic acid and ciclopirox olamine work synergistically to treat fungal and bacterial skin infections by keratolytic action and antifungal/antibacterial activity.

What is salicylic acid and ciclopirox olamine used for?

salicylic acid and ciclopirox olamine is indicated for Fungal skin infections (dermatophytosis, candidiasis), Onychomycosis (nail fungal infections), Bacterial skin infections.

Who makes salicylic acid and ciclopirox olamine?

salicylic acid and ciclopirox olamine is developed and marketed by Federal University of São Paulo (see full Federal University of São Paulo pipeline at /company/federal-university-of-s-o-paulo).

Is salicylic acid and ciclopirox olamine also known as anything else?

salicylic acid and ciclopirox olamine is also known as anti-seborrheic treatment, anti-dandruff treatment.

What drug class is salicylic acid and ciclopirox olamine in?

salicylic acid and ciclopirox olamine belongs to the Topical antifungal/keratolytic combination class. See all Topical antifungal/keratolytic combination drugs at /class/topical-antifungal-keratolytic-combination.

What development phase is salicylic acid and ciclopirox olamine in?

salicylic acid and ciclopirox olamine is FDA-approved (marketed).

What are the side effects of salicylic acid and ciclopirox olamine?

Common side effects of salicylic acid and ciclopirox olamine include Local irritation, Erythema, Pruritus, Contact dermatitis.

Related